Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results Regeneron Pharmaceuticals Q4 2024 Earnings Conference Call REGN February 2025 Corporate Presentation 2.6 MB

4 days ago · Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase ... except per share data) Q4 2024 Q4 2023 % Change FY 2024 FY 2023 % Change Total revenues $ 3,789 $ 3,434 10 % $ 14,202 $ 13,117 8 % GAAP net income $ 918 $ 1,160 (21 %) $ 4,413 $ 3,954 12 % ...

4 days ago · Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion ... Q4 2024 . Q4 ...

Regeneron Pharmaceuticals Q4 2023 Earnings Conference Call. Regeneron February 2024 Corporate Presentation 2.2 MB. Q4 2023 Earnings Conference Call Transcript 431.1 KB. Form 10-K. Q3 Regeneron Reports Third Quarter 2023 Financial and Operating Results. ... You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained ...

3 days ago · Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

3 days ago · Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported a strong fourth quarter with 10% revenue growth, driven by key franchises like Dupixent, Libtayo, and EYLEA. The company has a robust pipeline...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Conference Call February 4, 2025 8:30 AM ETCompany Participants. Ryan Crowe - SVP, IR Leonard Schleifer - Board Co-Chair, Co-Founder ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...

4 days ago · Q4 2024 : Q4 2023 % Change : FY 2024 : FY 2023 % Change: Total revenues $ 3,789 $ 3,434 : 10 % $ 14,202 $ 13,117 : 8 % ... Regeneron Pharmaceuticals Q4 2024 Earnings Preview. Seeking Alpha 17h.

3 days ago · Regeneron posted Q4 adjusted EPS of $12.07, beating the $11.29 consensus. Sales rose 10% to $3.79B, surpassing the $3.75B estimates. Eylea HD and Eylea U.S. sales grew 2% Y/Y to $1.49B, while ...